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Available online 31 December 2015α-Synuclein is a conserved, abundantly expressed protein that is partially localized in pre-synaptic terminals in
the central nervous system. The precise biological function(s) and structure of α-synuclein are under investiga-
tion. Recently, the native conformation and the presence of naturally occurringmultimeric assemblies have come
under debate. These are important deliberations becauseα-synuclein assembles into highly organized amyloid-
like ﬁbrils and non-amyloid amorphous aggregates that constitute the neuronal inclusions in Parkinson's disease
and related disorders. Therefore understanding the nature of the native and pathological conformations is pivotal
from the standpoint of therapeutic interventions that couldmaintainα-synuclein in its physiological state. In this
review, we will discuss the existing evidence that deﬁne the physiological states of α-synuclein and highlight
how the inherent structural ﬂexibility of this protein may be important in health and disease.
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α-Synuclein is a soluble protein that is highly conserved in verte-
brates and abundantly expressed in nervous tissue (Jakes et al., 1994).
It was ﬁrst discovered in 1988 in association with puriﬁed synaptic
vesicles from the Torpedo electric ray (Maroteaux et al., 1988). Soon
afterward α-synuclein was found to be widely distributed across the
mammalian brain and localized to presynaptic nerve terminals,
suggesting functions related to neurotransmission (Iwai et al., 1995). In-
dependent of these reports, α-synuclein was identiﬁed as the precursorthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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termed the non-Aβ component of Alzheimer's disease amyloid (NAC)
(Uéda et al., 1993). Theα-synuclein genewas also dynamically regulated
during song learning in zebraﬁnch, supporting a role in synaptic plasticity
(George et al., 1995).
The discovery of a mutation in the α-synuclein gene that was associ-
ated with autosomal dominant inheritance of Parkinson's disease
(PD) provided the impetus for a major shift in α-synuclein research
(Polymeropoulos et al., 1997). PD is a neurodegenerative disorder primar-
ily characterized by the loss of dopamine-producing neurons in the
substantia nigra pars compacta resulting in motor impairment. Since
the original publication of the A53T mutation, several mutations, as
well as multiplications of the α-synuclein gene have been linked to PD
(Chartier-Harlin et al., 2004; Krüger et al., 1998; Lesage et al., 2013;
Pasanen et al., 2014; Proukakis et al., 2013; Singleton et al., 2003; Zarranz
et al., 2004; Ferese et al., 2015) Furthermore, several antibodies against
α-synuclein robustly detect the well-known pathoanatomical features
of PD, Lewy bodies and Lewy neurites, in postmortem brain tissue from
patients with sporadic PD as well as other related neurodegenerative
disorders (Baba et al., 1998; Spillantini et al., 1997; Takeda et al., 1998).
The ﬁnding that wildtype α-synuclein was detected in Lewy bodies and
Lewy neurites prompted the publication of numerous studies that
investigated the biochemistry and biology of α-synuclein. Despite the
rather impressive body of work several fundamental questions remain:
What is the physiological function of α-synuclein? What is the structure
of native α-synuclein? What factors contribute to the induction of
aggregation-competent conformational states of α-synuclein? In this
review, we will brieﬂy review the evidence for the different biological
functions and discuss ongoing efforts to precisely deﬁne physiological
structures of α-synuclein.
2. The physiological function(s) of α-synuclein
The initial studies indicated thatα-synuclein is not required for neuro-
nal development or synapse formation, but insteadmaymodulate synap-
tic activity. In rodents, α-synuclein is detected close to the time of birth
and continues to increase until one month of age, when it reaches a
steady-state level that is maintained throughout adulthood (Shibayama-
Imazu et al., 1993). Similarly, in cultured rat neurons the development
of synapses precedes α-synuclein expression and translocation to axonal
terminals (Murphy et al., 2000;Withers et al., 1997). The hypothesis that
α-synuclein regulates synaptic activitywas directly tested inmice lacking
α-synuclein. α-Synuclein null mice develop normal brain architecture
and synaptic contacts, and do not exhibit gross behavioral phenotypes
(Abeliovich et al., 2000). However, subtle abnormalities in activity-
dependent neurotransmitter release have been observed. Upon repeated
stimulation, dopaminergic synapses from α-synuclein null mice sustain
highly elevated dopamine release (Abeliovich et al., 2000; Yavich et al.,
2004). Functional redundancy amongα-synuclein and the other synucle-
in family members, β- and γ-synuclein, may account for the mild pheno-
types observed in the single knockout. Inα/β-synuclein double knockout
mice, synaptic plasticity appears unaltered relative to α-synuclein single
knockouts, although dopamine levels in the striatum are reduced
(Chandra et al., 2004). The importance of synucleins is particularly
highlighted by α/β/γ-synuclein triple knockouts, which have decreased
life span and late-onset synaptic dysfunction compared with wildtype
mice (Burré et al., 2010; Greten-Harrison et al., 2010). Triple knockouts
in another study had motor deﬁcits and decreased striatal dopamine,
along with abnormal dopamine neurotransmission (Anwar et al., 2011).
Collectively, these reports emphasize the important role of the synucleins
in long-term synaptic maintenance and plasticity.
2.1. Synaptic vesicle trafﬁcking
Examination of the role of α-synuclein in the synaptic vesicle cycle
has yielded conﬂicting results. Depletion of α-synuclein from rodenthippocampal neurons both in vivo and in vitro induces a signiﬁcant
loss of undocked synaptic vesicles, suggesting that α-synuclein acts to
replenish or maintain the resting and/or reserve vesicle pools (Cabin
et al., 2002; Murphy et al., 2000). In contrast, another study found that
increasing α-synuclein in rodent hippocampal neurons reduces
the recycling pool of vesicles (Nemani et al., 2010). The effect of
α-synuclein on vesicles docked at the plasmamembrane prior to exocy-
tosis is similarly unclear. Knockout or knockdown of α-synuclein in
rodent hippocampal neurons results in either a decrease or no change
in the number of docked vesicles (Cabin et al., 2002; Murphy et al.,
2000). Conversely α-synuclein expression in PC12 cells causes an
accumulation of vesicles at the plasma membrane and impairment of
exocytosis (Larsen et al., 2006). However, in mice modestly overex-
pressing α-synuclein (levels are not associated with neurotoxicity),
hippocampal synapses display a redistribution of vesicles away from
the active zone. The density of vesicles in synaptic boutons is also
reduced, consistent with α-synuclein-mediated inhibition of vesicle
clustering. This is supported by α-synuclein-induced defects in vesicle
re-clustering following endocytosis in rat hippocampal neurons
(Nemani et al., 2010). Still, opposing results have been obtained from
yeast, in which α-synuclein expression results in massive accumula-
tions of vesicles that co-localize with Rab GTPases (Gitler et al., 2008;
Soper et al., 2008). Likewise, α-synuclein has been shown to restrict
vesicle diffusion away from synapses in mouse hippocampal neurons
(Wang et al., 2014). Several lines of evidence, therefore, support the
participation of α-synuclein in synaptic vesicle trafﬁcking, though the
speciﬁc steps for which it may be most important, i.e. vesicle docking,
recycling and/or re-clustering, remain unclear.
2.2. Chaperone-like activity and neurotransmitter release
α-Synuclein and the other synuclein family members may act as
molecular chaperones, facilitating neurotransmitter release. Cysteine-
string protein α (CSPα) is a chaperone that is essential for synaptic
health; its deletion in mice leads to a decrease in SNARE protein com-
plexes, nerve terminal degeneration, motor impairment and death.
When expressed in CSPα-deﬁcient mice, α-synuclein is able to rescue
this degenerative phenotype and restore levels of SNARE complexes in
synaptic terminals. Moreover, mice lacking both α-synuclein and
CSPα exhibit an exacerbated phenotypic decline (Chandra et al.,
2005). These ﬁndings suggest that α-synuclein is able to complement
the activity of CSPα in promoting synapse integrity. Direct evidence
for the interaction of α-synuclein with SNARE complexes was
documented by co-immunoprecipitation of α-synuclein with SNARE
proteins and speciﬁc binding to the vesicle-associated SNARE protein
synaptobrevin-2. In mammalian cells and puriﬁed in vitro systems, α-
synuclein dose-dependently facilitates SNARE complex assembly
(Burré et al., 2010). Additional support for chaperone-like activity in-
cludes sequence homology between α-synuclein and 14-3-3 protein
chaperones as well as the association of α-synuclein with 14-3-3 and
its binding partners in rat brain (Ostrerova et al., 1999). α-, β-, and
γ-synucleins are also able to prevent the aggregation of denatured
proteins in vitro (Souza et al., 2000a), further supporting a conserved
chaperone-like function of synucleins and the existence of several pro-
tein–protein interactions that facilitate synaptic function.
2.3. Putative role in neurotransmitter synthesis and reuptake
Published evidence indicates that α-synuclein-mediated protein-
protein interactions may modulate dopamine synthesis and recycling.
α-Synuclein may inhibit the activity of tyrosine hydroxylase (TH), the
rate-limiting enzyme in dopamine synthesis. α-Synuclein and TH co-
immunoprecipitate from rat striatal tissue and MN9D dopaminergic
cells and α-synuclein was shown to inhibit TH activity in MN9D and
PC12 cells, potentially through PP2A phosphatase-mediated reduction
of serine 40 phosphorylation of TH (Peng et al., 2005; Perez et al.,
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aromatic amino acid decarboxylase, which catalyzes the conversion of
L-DOPA to dopamine (Tehranian et al., 2006). Thus, α-synuclein may
serve as a negative regulator of dopamine synthesis, though further
validation of these ﬁndings is necessary. Several reports have also impli-
cated α-synuclein in the regulation of the dopamine transporter (DAT),
though the evidence is conﬂicting with regards to the functional conse-
quences. Direct binding of α-synuclein to DAT has been demonstrated
in multiple studies. However, α-synuclein does not appear to alter
DAT function, but rather in various cellular contexts can promote or
inhibit DAT trafﬁcking to the plasma membrane (Oaks and Sidhu,
2011). Elucidating the relationship between α-synuclein and DAT
requires further investigation.3. α-Synuclein structural ﬂexibility
3.1. Primary sequence
The primary sequence of α-synuclein consists of 140 amino acids
with a predicted molecular mass of 14,460.16 Da and an isoelectric
point of 4.67 (Fig. 1). The sequence of α-synuclein is composed of
three functionally deﬁned domains. The N-terminal region (amino
acids 1–60) is characterized by the presence of unique and highly con-
served sequence of imperfect tandem repeats with a central consensus
motif of K(A)–T(A,V)–K(V)–E(Q,T)–G(Q)–V(A). These motifs spanning
residues 10–86 are projected to form two amphipathic α-helices and
are characteristic of several proteins such as apolipoproteins that bind
reversibly to membranes (George et al., 1995; Maroteaux et al., 1988).
Indeed the structure of membrane bound α-synuclein contains two
α-helices (amino acids 3–37 and 45–92) in a roughly antiparallel ar-
rangementwith a short linking region (Ulmer et al., 2005). These helices
are stabilized by interaction with a variety of phospholipid bilayers,
though α-synuclein interacts preferentially with membranes of
high curvature and an abundance of acidic phospholipids, properties
consistent with those of synaptic vesicles (Davidson et al., 1998; Zhu
et al., 2003). Upon interaction with membranes of low curvature
α-synuclein adopts a distinct secondary structure characterized by a
single extended helix that includes both previously described helical
domains and the linker region (amino acids 38–44) (Ferreon et al.,
2009; Georgieva et al., 2010; Trexler and Rhoades, 2009). All known
mutations associated with familial PD (A30P, E46K, H50Q, G51D,
A53E, and A53T) are found in the N-terminal domain (Krüger et al.,
2008; Lesage et al., 2013; Pasanen et al., 2014; Polymeropoulos et al.,
1997; Proukakis et al., 2013; Zarranz et al., 2004). These mutations,
with the exception of G51D, A53E, and A30P, increase the propensity
of α-synuclein to form insoluble aggregates and produce morphologi-
cally distinct aggregate species (Ghosh et al., 2014; Giasson et al.,
1999; Greenbaum et al., 2005; Lesage et al., 2013; Mahul-Mellier et al.,
2015; Narhi et al., 1999). Though the precise mechanism by which
these mutations promote aggregation has not been conclusively
shown, evidence implicate an accelerated formation of oligomers
(Conway et al., 2000) likely due to the destabilization of the nativeFig. 1. Primary sequence of human α-synuclein. Green color indicates the imperfect tandem re
The major sites of posttranslational modiﬁcations identiﬁed in vivo are highlighted in blue (AcN-terminal conformation (Bertoncini et al., 2005a; Burré et al., 2015;
Coskuner and Wise-Scira, 2013; Dettmer et al., 2015).
Amino acids 61–95 compose the hydrophobic NAC domain (Uéda
et al., 1993). This region contains a sequence of amino acids (71–82)
necessary and sufﬁcient for α-synuclein self-assembly into amyloid ﬁ-
brils (Giasson et al., 2001). Recently the crystal structures of residues
68–78 (termed NACore), and residues 47–56 (PreNAC) were resolved
by the use of micro-electron diffraction, revealing that strands in this
region stack in-register into β-sheets that are typical of amyloid assem-
blies (Rodriguez et al., 2015).
The C-terminal domain (96–140) is rich in negatively charged amino
acids (contains 10 glutamate and 5 aspartate residues) and was
originally proposed to be essential for maintaining the solubility of the
protein. The presence of 5 proline residues, which are known to induce
turns and disrupt secondary protein structure, suggested that this re-
gion is devoid of secondary structure (George et al., 1995; Ulmer et al.,
2005). However, the C-terminus was shown to form transient, long-
range interactions with the N-terminus resulting in the formation of
multiple compact monomeric structures (Bertoncini et al., 2005a;
Dedmon et al., 2005). These compacted structures of α-synuclein are
temperature sensitive and are resistant to aggregation. The data also
indicated that at elevated temperatures the C-terminus assumes an
extended conformation that liberates N-terminal associations and en-
ables aggregation (Bertoncini et al., 2005b; Dedmon et al., 2005).
Moreover, C-terminally truncated forms ofα-synuclein aggregate faster
than full length protein (Hoyer et al., 2004; Li et al., 2005). Truncated
α-synuclein has been detected in the brains of both control (non-disease)
and PD patients. Cleavage of full-length protein at residues D115, D119,
N122, D125 and Y133 was documented in α-synuclein extracted from
LBs (Anderson et al., 2006).
The C-terminus appears to be important for the interaction of
α-synuclein with other proteins and for the interaction with small mol-
ecules (Burré et al., 2012; Burré et al., 2010; Conway et al., 2001;
Mazzulli et al., 2006; Souza et al., 2000b; Woods et al., 2007). Addition-
ally, it contains the major sites of metal binding and post-translational
modiﬁcations. Binding of iron, copper, and other metals has been
shown to inﬂuence α-synuclein function and aggregation (Uversky
et al., 2001a). Addition of Fe(III), but not Fe(II) to preformed oligomers
of α-synuclein accelerates aggregation, raising the question of metal
binding at different points during the aggregation process (Kostka
et al., 2008). Cu(II) is unique among metals at accelerating aggregation
ofα-synuclein at physiologically relevant concentrations. The sole histi-
dine residue H50 inα-synuclein was found to be critical for Cu(II) bind-
ing (Rasia et al., 2005) whereas other divalent metal ions, including
Mn(II), Co(II), Ni(II) and Fe(II), preferentially bind to the C-terminus
of α-synuclein at residues D121, N122, and E123 (Binolﬁ et al., 2006).
3.2. Post-translational modiﬁcations
α-Synuclein undergoes a number of post-translational modiﬁca-
tions, including N-terminal acetylation, serine and tyrosine phosphory-
lation, lysine ubiquitination and tyrosine nitration (Oueslati et al., 2010;
Barrett and Greenamyre, 2015). α-Synuclein puriﬁed under mildpeats. Knownmutations are indicated in red. The hydrophobic NAC domain is underlined.
, acetylation; Ub, ubiquitination; NO2, nitration; and PO3− phosphorylation).
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may account for the formation of an oligomeric form of the protein
with partial α-helical structure (Trexler and Rhoades, 2012). However,
semisynthetic production of N-terminally acetylated α-synuclein dem-
onstrated that modiﬁed and unmodiﬁed versions of the protein share
similar secondary structure, aggregation propensities, and membrane
binding (Fauvet et al., 2012). NMR studies indicated that theﬁrst 12 res-
idues undergo a chemical shift due to N-terminal acetylation. This mod-
iﬁcation also appears to stabilize the helicity of the N-terminus within
the context of the full-length protein, and increases the afﬁnity of α-
synuclein for lipids (Dikiy and Eliezer, 2014).
Mass spectrometry-based methodologies revealed that α-synuclein
extracted from human Lewy bodies was phosphorylated at S129
(Fujiwara et al., 2002). An antibody raised against phosphorylated
S129 was then used to show that α-synuclein was phosphorylated at
this site only in subjects with disease and that S129 phosphorylated
α-synuclein was present only in the Triton-X- and Sarkosyl-insoluble,
urea soluble fraction. These data indicated that some form(s) of aggre-
gatedα-synuclein and not the soluble protein is targeted for phosphor-
ylation at S129. Indeed in vitro data showed that puriﬁed ﬁbrils of
α-synuclein are substrates for casein kinase 1 or 2 (Waxman and
Giasson, 2008). Other data indicated that polo-like kinase (PLK)
2-mediated phosphorylation of S129 increased autophagy-mediated
degradation of α-synuclein, suggesting that phosphorylation may be a
neuroprotective mechanism to accelerate clearance of aggregated pro-
tein (Oueslati et al., 2013). In addition to the monomeric α-synuclein,
S129 phosphorylated bands with apparent molecular weight of
22 kDa and 29 kDa were observed in the detergent insoluble extract
(Hasegawa et al., 2002). These bands were also immunoreactive with
anti-ubiquitin antibodies suggesting that S129 phosphorylated
α-synuclein is also targeted for mono- and di-ubiquitination. It has
long been established that the core of Lewy bodies stains positive for
bothα-synuclein and ubiquitin whereas the surrounding halo is immu-
noreactive for α-synuclein (Hasegawa et al., 2002). Of the 15 lysine
residues in α-synuclein, the major sites of LB-derived α-synuclein un-
dergoing ubiquitination were residues K12, K21, and K23 (Anderson
et al., 2006; Hasegawa et al., 2002; Sampathu et al., 2003).
A number of spectroscopic methodologies (CD and NMR) were
employed to explore the effect of S129phosphorylation on the structure
of α-synuclein. CD data revealed that phosphorylation of S129 did not
affect secondary structure, such that both non-phosphorylated and
phosphorylated S129 exhibited random coil structure (Paleologou
et al., 2008). NMR data revealed a number of chemical shifts that
occur due to phosphorylation. While the residues surrounding S129
exhibited the greatest perturbation, residues 1–90 also exhibited
detectable chemical shifts (Paleologou et al., 2008) This likely reﬂects
the previously documented long-range interactions of the C- and
N-termini. The potential effects of phosphorylation of S129 on the struc-
ture of the protein were not faithfully reproduced by mutation of S129
to either E or D, two common phosphomimics used to study the struc-
tural consequences of phosphorylation. For example, phosphorylation
at S129 increased the hydrodynamic radius of the protein, whereas
S129 E/D mutants did not (Paleologou et al., 2008).
Subsequent studies found additional sites of phosphorylation.
Elevated levels of phosphorylated α-synuclein at residue S87 were de-
tected in human brains with Alzheimer's disease, Lewy Body disorders,
and multiple system atrophy (Paleologou et al., 2010). S87 phosphory-
lation alters the biophysical properties of α-synuclein, including inhibi-
tion of ﬁbril formation and reduction inmembrane binding (Paleologou
et al., 2010). Additionally, phosphorylated α-synuclein at residue Y125
was detected in Drosophila expressing human wildtype α-synuclein
as well as in human brains, though levels were decreased in disease
compared with aged-matched healthy controls (Chen et al., 2009).
The proximity of theα-synuclein phosphorylation sites to themetal
binding sites raised the question of how phosphorylation may affect
metal ion interactions. This was investigated by the use of C-terminalpeptides containing residues 119–132 that were either unmodiﬁed,
phosphorylated at Y125 or at S129 (Liu and Franz, 2005). By exploiting
the luminescence properties of Tb3+, it was found that phosphorylated
Y125 showed enhanced Tb3+ binding relative to wildtype or phosphor-
ylated S129. Additionally, phosphorylated Y125 preferentially bound to
trivalent rather than divalent metal ions. To investigate this further,
longer C-terminal fragments comprised of residues 107–140 that were
either unmodiﬁed of monophosphorylated at Y125 or S129were tested
for their afﬁnity to various metal ions. By using a ﬂuorescence
quenching assay, the dissociation constants of the metal ion complexes
and theα-synuclein peptideswere determined. These data indicate that
either phosphorylation at Y125 or S129 increases the binding afﬁnity for
Cu (II) and Fe(II), but not Fe(III). Furthermore, phosphorylated Y125 has
a greater afﬁnity for Pb(II) than wildtype, but phosphorylated S129 has
an even greater afﬁnity than phosphorylated Y125. Additionally, tan-
dem MS indicated that phosphorylation causes the metal ion binding
sites to shift towards the C-terminal end ofα-synuclein (Lu et al., 2011).
α-Synuclein within Lewy bodies is nitrated on all four tyrosine resi-
dues (Giasson et al., 2000). Chemical nitration of α-synuclein results in
the formation of both tyrosine nitrated monomers and nitrated dimers
(Souza et al., 2000b). Immunoelectron microscopy conﬁrmed that
nitrated monomers and dimers are incorporated into amyloid ﬁbrils.
Puriﬁed nitrated α-synuclein monomer by itself was unable to form ﬁ-
brils, whereas the nitrated dimer accelerated aggregation of unmodiﬁed
α-synuclein (Hodara et al., 2004). Additionally, nitration at residue Y39
in the N-terminus decreased binding to synthetic vesicles and
prevented the protein from adopting α-helical conformation (Hodara
et al., 2004). These observations were recently conﬁrmed and elegantly
expanded by the generation of site-speciﬁcally nitrated α-synuclein
using protein semisynthetic chemistries (Burai et al., 2015). Using the
synthetic nitrated α-synuclein the data showed that nitration did not
interfere with phosphorylation of S129 by PLK3 and reafﬁrmed that
intermolecular interactions between the N- and C-terminal regions of
α-synuclein are critical in directing nitration-induced oligomerization
of α-synuclein (Burai et al., 2015).
3.3. Native conformation(s) of α-synuclein
Fig. 2 depicts the rapid growth in the number of publications identi-
ﬁed in PubMed using the term synuclein and highlights key studies that
explored the native structure and conformation of the protein. Early
biochemical studies of α-synuclein isolated from bacterial expression
systems or α-synuclein expressed in rodent tissues indicated that it is
monomeric with limited secondary structure. Electrophoretic separa-
tion ofα-synuclein puriﬁedwithout heating on 6, 10, or 14% acrylamide
gels estimated an apparent molecular weight of 20 ± 3 kDa. However,
the values of sedimentation coefﬁcient (S20,w = 1.7S), stokes radius
(34 Å), analysis on native gels and derivation of the frictional coefﬁcient
(f/fo = 2.09) indicated an apparent molecular weight in the range
57–58 kDa (Weinreb et al., 1996). To reconcile this apparently anoma-
lous behavior it was proposed that monomeric α-synuclein achieves
minimal structure in simple solutions and this rather extended unstruc-
tured conformation resembles a globular protein with a larger apparent
molecular weight. This assumption was further corroborated by exam-
ination of puriﬁed monomeric α-synuclein by CD, FTIR and small
angle X-ray scattering, which failed to identify signiﬁcant secondary
structural features. Furthermore, minimal shifts in the spectroscopic
features of α-synuclein were observed when the protein was placed
in solutions that would increase hydrophobicity and neutralize neg-
ative charges indicating that the protein is natively unstructured,
joining a growing group of proteins sharing similar biochemical
and biophysical characteristics (Uversky et al., 2001b). NMR and
CD data, however, indicated that α-synuclein assumes increasingly
folded secondary structure when exposed to conditions that pro-
mote aggregation (low pH and high temperature) or upon interac-
tion with phospholipids. Collectively these data indicated that
Fig. 2.The graph depicts the number of publications retrieved fromPubMedusing the search term “alpha synuclein” froma single publication in 1998 to 862 in2015. Signiﬁcantmilestones
that examined the native structure and conformations of α-synuclein are displayed.
70 D.E. Mor et al. / Neurobiology of Disease 88 (2016) 66–74native α-synuclein is primarily an unstructured monomer, which
can assume different compact conformations that resist aggre-
gation, adopts α-helical conformation upon binding to lipids and
undergoes conformational changes prior to oligomerization and for-
mation of amyloid ﬁbrils (Uversky et al., 2001b). However,
the methodologies employed to quantify the molecular weight of
α-synuclein in these elegant studies were not based on ﬁrst princi-
ples and therefore a lingering uncertainty remains regarding the
native size of the protein. Moreover, crosslinking experiments in
both intact cells expressing α-synuclein and lipid-free lysates re-
vealed the stabilization of high molecular weight α-synuclein
multimers (consistent with dimers, trimers, and larger multimers).
These multimers were not reduced by dilution of lysates before
crosslinking, nor by reducing the concentration of crosslinker from
1 mM to 8 μM, suggesting that they represented endogenous protein
complexes (Cole et al., 2002).
Examination of the α-synuclein native state was reignited in 2011
with the publication of results indicating thatα-synuclein exists native-
ly as a tetramer, rather than a monomer. Methodologies that are based
on ﬁrst principles were employed to examine themolecular weight and
size of α-synuclein extracted under non-denaturing conditions from
human red blood cells. Analytical ultracentrifugation produced a
sedimentation equilibrium value of 4.78 S, indicating a molecular
weight of 57.8 kDa. Analysis of particle geometry by scanning transmis-
sion electron microscopy revealed the presence of roughly spherical
molecules with a diameter of approximately 3.0–3.5 nm. Automated
sampling of 1000α-synuclein particles showed a distribution of molec-
ular weights between 10 and 175 kDa with a peak distribution at
55 kDa. These ﬁndings constitute the most direct measurements of the
native molecular weight of α-synuclein. The tetrameric species were
shown to have α-helical conformation and were resistant to aggrega-
tion (Bartels et al., 2011).
Complimentary observations were made using recombinant
GST-tagged α-synuclein puriﬁed from bacterial expression systems
under non-denaturing conditions. Single-particle electron microscopy
of puriﬁed α-synuclein revealed complexes of sizes and internal geom-
etries consistent with trimers and dimers, which were corroborated by
measurements of the hydrodynamic radii and elution on native state
PAGE. As observed previously, these species were more resistant to
aggregation than denatured monomer. CD also showed that severalα-synuclein mutations associated with early onset PD (A30P, E46K,
A53T) exist in less ordered conformations than wildtype α-synuclein.
These mutants were also more prone to aggregation (Wang et al.,
2011). However, using the same α-synuclein construct that contains a
10-residueN-terminal extension,which formsmultimerswhen isolated
from Escherichia coli, NMR studies indicated that only a small fraction of
α-synuclein assembles into α-helical trimers and tetramers and the
majority remains as a disordered monomer (Gurry et al., 2013). These
data indicated that several potential conformers of α-synuclein may
exist in equilibrium. The observation that α-helical trimers and tetra-
mers constitute only a small fraction of the total α-synuclein may
explain other studies in which in-cell NMR was used to probe for the
structure of α-synuclein and reported primarily the presence of un-
structured monomer. NMR data of α-synuclein in intact cells failed to
detect stable or highly populatedα-synucleinmultimers and conﬁrmed
the intrinsically disordered nature of the protein in Escherichia coli re-
gardless of its puriﬁcation method (Binolﬁ et al., 2012). Collectively
these studies generated an apparent controversy and stimulated several
additional studies that explored the native size and structure of α-
synuclein.
A re-examination of the native state of α-synuclein reasserted that
the behavior of α-synuclein from various sources was consistent with
a disordered monomer. This behavior was observed with protein
extracted and isolated under both denaturing and non-denaturing
conditions. CD spectra previously attributed to tetrameric assemblies
were not reproduced using isolated monomer, but were replicated
with the addition of small unilamellar vesicles. Natively isolated
α-synuclein before or after boiling that disrupts secondary structuremi-
grated as high molecular weight α-synuclein bands in native PAGE,
which was attributed to the rather expanded size of the unstructured
monomer in solution. These ﬁndings reafﬁrmed that themajority of na-
tive α-synuclein is a monomer with minimal secondary structure
(Fauvet et al., 2012). Further support was provided by similar explora-
tions in the mouse brain, which indicated that the predominant native
form of α-synuclein is an unstructured monomer. α-Synuclein exhibit-
ed random coil structure in solution, readily aggregated over time, and
adopted α-helical structure only upon membrane binding (Burré
et al., 2013).
α-Synuclein multimers were detected in postmortem non-diseased
human brain using mild protein extraction methods, but no further
71D.E. Mor et al. / Neurobiology of Disease 88 (2016) 66–74puriﬁcation. These α-synuclein multimers had Stokes radii ranging
from 33.2–37.5 Å, sedimentation coefﬁcients ranging from 1.4S to 3.8S
and apparent molecular weights ranging from 53–70 kDa in native gra-
dient gels. Themultimers were detected by anti-α-synuclein antibodies
that recognize different epitopes and the multimer identity was con-
ﬁrmed by mass spectrometry. Consistent with previous observations,
melting point thermostability analysis showed progressive loss of the
α-synuclein multimers and heating of the brain extracts above 55 °C
collapsed the higher molecular weight α-synuclein conformers into
the 53 kDa species, which corresponds to the unstructured monomer.
These data indicated the presence of α-synuclein conformers, deﬁned
as conformationally diverse α-synuclein multimers, in the human
brain. Therefore it appears that both monomer and metastable
multimers coexist and that interactions with lipids, other proteins, or
small molecules may transiently stabilize these species (Gould et al.,
2014). This was further supported by controlled bimolecular ﬂuores-
cence complementation methodologies in different cell types that
found α-synuclein metastable conformers assembled in synapses. It
was suggested that the function of these multimeric α-synuclein
conformers is to restrict recycling of synaptic vesicles and thus reduce
neurotransmitter release (Wang et al., 2014).
Additional support for native multimeric species comes from recent
studies in which serial puriﬁcation of α-synuclein from non-
pathological human cortical tissue was performed. Removal of lysate
components other than protein followed by sequential removal of
proteins though size exclusion, anion chromatography, and thiopropyl
sepharose 6b separation, resulted in the isolation of N90% pure
α-synuclein. Each step of serial puriﬁcation resulted in a progressive
loss of α-synuclein immunoreactive high molecular weight bands
observed after disuccinimidyl glutarate crosslinking and SDS-PAGE
separation. Analysis of α-synuclein secondary structure by CD found
that the sequentially puriﬁed protein had greater α-helical content
than the recombinant α-synuclein. However, a high degree of variabil-
ity in secondary structure was observed between puriﬁed samples
raising questions about the stability of these helical conformations
(Luth et al., 2015). Furthermore, crosslinking experiments conducted
in brain tissue from mice expressing wildtype or A53T human
α-synuclein in the absence of mouse α-synuclein showed that
the A53T mutation reduced the presence of soluble multimeric
α-synuclein (Dettmer et al., 2015).Fig. 3. Free energy landscape of possible α-synuclein conformers andmultimeric assemblies. Th
dissociation from stabilizing interactions with lipids and/or proteins as well as dissociation of th
assemble into dimers and larger oligomeric conformers. The generation of α-synuclein oligo
aggregates, both of which have been observed in postmortem brain tissue from patients with4. Concluding remarks and perspectives
Collectively the studies on the native structure indicate a remarkable
conformational plasticity and structural ﬂexibility of α-synuclein. The
ability of the protein to adopt N-terminal α-helical conformation
through its associationwith lipids has beenwell documented. The asso-
ciationwith lipids has been shown to preventﬁbril formation (Martinez
et al., 2007; Zhu and Fink, 2003) and may also stabilize physiological
multimeric species that together with the monomer regulate SNARE
complex assembly and recycling of synaptic vesicles (Burré et al.,
2014; Wang et al., 2014). However, other groups have demonstrated
a role for phospholipid membranes in promoting pathological
α-synuclein aggregation, potentially by acting as a scaffold for amyloid
nucleation. This event may preferentially occur at low lipid to protein
ratios, when monomeric α-synuclein is free in solution and can partici-
pate in nucleation (Galvagnion et al., 2015; Ysselstein et al., 2015).
In Fig. 3 we propose a model which incorporates and summarizes
the existing knowledge regarding α-synuclein biology and structure.
The steady state levels ofα-synuclein are carefully regulated by protein
synthesis and removal by several pathways such as the ubiquitin-
proteasome pathways and autophagy (Webb et al., 2003). Controlling
the steady state levels of this protein by regulating synthesis anddegrada-
tionmaybe theﬁrst critical defense in preventing aggregation. Conforma-
tional change to α-helical rich structures, and stabilization of metastable
multimers is achieved by speciﬁc interactions with vesicular phospho-
lipids and proteins. The sequestration of α-synuclein in association with
membrane vesicles andwith other proteinsmay be of critical importance
for preventing aggregation. Therefore these dynamic equilibria maintain
functionality and promote assemblies that are resistant to aggregation.
Catastrophic events that may include inappropriate post-translational
modiﬁcations will disassemble the multimers as well as transform
aggregation-incompetent monomers to aggregation-competent species.
The ﬁrst step in the pathway to amyloid ﬁbril formation is the generation
of a dimer that is either held together by hydrophobic interactions
induced by increased conformational transition to β-sheet structure or
upon covalent cross-linking. Following this nucleation event (Wood
et al., 1999) the hydrophobic patch of amino acids between residues
71–82 appears to be primarily responsible for allowing additional
α-synuclein monomers to assemble to form oligomeric structures. This
transition is the committed rate limiting step for aggregation and muste conversion of nativeα-synuclein to aggregation-competent monomers may depend on
emetastable tetrameric species.α-Synuclein aggregation-competent monomers can then
mers can rapidly lead to formation of stable amyloid ﬁbrils, or ‘off-pathway’ amorphous
PD and related disorders.
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conversion from an unstructured coil to organized β-sheet conformation.
Oligomers are soluble in aqueousbuffers and can appear spherical or ring-
like by atomic force and electron microscopy (Conway et al., 2000;
Lashuel et al., 2002). Soluble, high molecular weight oligomers have
been extracted from human brain tissue and their levels appear to be
increased in PD brain (Sharon et al., 2003) as well as mouse models of
α-synuclein aggregation (Tsika et al., 2010). As oligomers grow, they
reach an undeﬁned critical length and are able to assume additional qua-
ternary structure. At this stage, these structures may continue to grow in
linear β-sheets, forming polarized protoﬁbrils and eventually ﬁbrils. Fi-
brils may further arrange into protein inclusions although it remains
unclear if other proteins within these inclusions anchor these ﬁbrils.
Alternatively, oligomers may remain soluble by interacting with small
molecules (Conway et al., 2001) or by incorporating post-translationally
modiﬁed α-synuclein molecules. These structures remain “off the amy-
loid ﬁbril pathway” and may constitute what has been described in
human postmortem tissue as “dots” or “dust-like” amorphous aggregates
(Braak et al., 2001; Duda et al., 2002). At this juncture, it remains unclear
which of these assemblies are toxic to neurons. Recent data indicate that
several conformationally distinct assemblies (possibly different strains) of
α-synuclein generated in vitrowill induce the aggregation of endogenous
α-synuclein resulting in neurodegeneration (Guo et al., 2013; Luk et al.,
2012; Peelaerts et al., 2015; Sacino et al., 2014). The appreciation of differ-
ent α-synuclein conformers and assemblies as well as their roles in
disease may guide potential therapeutic approaches. For example, thera-
peutic strategies can be centered on preserving and stabilizing the physi-
ological multimeric conformers as well as preventing monomers from
aggregating. Alternatively, sequestration and removal of aggregation-
competent monomers and oligomers can be considered.Acknowledgments
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